Figure 3.

Consistency between OptiSeq^TM lung cancer fusion NGS panel and Qfusion^TM ALK, RET, or ROS1 fusion detection assay results. (a) Analysis of twenty FFPE samples using the OptiSeq^TM lung cancer fusion NGS panel revealed the presence of SLC34A2-ROS1 fusion in two patient samples. The Y-axis represents normalized reads, and the error bars indicate the standard deviations of three replicates. (b) The same twenty FFPE samples were subjected to analysis using Qfusion^TM assays. The results confirmed ROS1 fusion positivity in two patients with SLC34A2-ROS1 fusion. Qfusion^TM ALK and RET fusion detection assays showed no ALK and RET fusions. The error bars depict the standard deviations of three replicates.